Corporate Profile

Enlivex is the first and only stock that provides investors with exposure to prediction markets, through a treasury strategy focused on the most exciting prediction markets protocol, Rain. In addition, Enlivex has an operating business focused on late-stage clinical development of Allocetra™, a novel therapy designed to treat the joint disease osteoarthritis.

Osteoarthritis is by far the most common form of arthritis, affecting more than 32.5 million Americans and more than 300 million individuals worldwide. About half of knees with ACL injuries develop osteoarthritis within 5 to 15 years. 78 million Americans are projected to have osteoarthritis by the year 2040. Symptomatic knee osteoarthritis is particularly prevalent and disabling, with 40% of men and 47% of women developing knee osteoarthritis in their lifetimes. Osteoarthritis accounts for over one million hospitalizations annually in the United States, primarily for total joint replacement. The burden of osteoarthritis is enormous, and the need for treatments that reduce pain and attendant disability for persons with osteoarthritis is critical. To Enlivex’s knowledge, there are currently no medications approved by either the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) that have been demonstrated to arrest, slow or reverse progression of structural damage in the joint.

Enlivex drives shareholder value through two parallel engines: developing Allocetra™ for immune rebalancing and managing an active digital asset treasury anchored by the Rain prediction markets protocol

Investment Highlights

1

Seasoned management team with a track record of advancing therapies through regulatory approval.

2

Rain is a fully decentralized prediction markets protocol built on the Arbitrum network.

3

Rain stands out compared to other players in the sector.

4

Deflationary token economics strengthen the DAT strategy.

5

Enlivex is the world's first and only Rain treasury company.

6

Clinical development pipeline addressing a multi-billion-dollar market opportunity.

Recent Press Releases

2

November

2026

In patients aged 64+: 79.2% of patients achieved a clinically meaningful response (reduced pain and improved knee function) in the Allocetra™ group vs. 47.6% in the placebo group at 12 months (p=0.027)1 Allocetra™ treatment benefit at 12 months was consistent with the response rates obse...
28

October

2026

135 patients, out of a total planned 182, have been randomized and were administered the first injection of AllocetraTM; enrollment actively ongoing at clinical sites in the United States and in Europe Topline six-month data expected by mid-2027 Phase 2b builds on positive thr...
27

October

2026

Nes-Ziona, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced receipt of a delisting notification dated October 26, 2026 (the "Delisting Notice") from the Listing...